The positive role of METCAM/MCU18 in the progression of breast cancer is very likely to be similar to that in melanoma and prostate cancer [3,6-10,32]; thus METCAM/MUC18 may be a potential therapeutic target for an alternative treatment of breast cancer [35,36]. This evidence concerns the gene MCAM and prostate carcinoma.